

Listing of the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1-67. (Cancelled)
68. (Previously presented) A substantially pure SARS virus nucleic acid molecule.
69. (Previously presented) The molecule of claim 68, wherein said molecule is selected from the group consisting of genomic RNA or DNA, cDNA, synthetic DNA, or mRNA.
70. (Previously presented) The molecule of claim 68, wherein said molecule comprises a sequence substantially identical to a sequence selected from the group consisting of SEQ ID NOs: 1-13, 15-18, 20-30, 90-159, 208, and 209 or a fragment thereof.
71. (Previously presented) The molecule of claim 70, wherein said molecule comprises a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO:2, and SEQ ID NO: 15 or a fragment thereof.
72. (Previously presented) The molecule of claim 70, wherein said molecule comprises a sequence substantially identical to a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO:2, and SEQ ID NO: 15 or a fragment thereof.
73. (Previously presented) The molecule of claim 68, wherein said molecule comprises a s2m motif.
74. (Previously presented) The molecule of claim 73, wherein said s2m motif comprises a sequence substantially identical to a sequence selected from the group consisting of SEQ ID NOs: 16, 17, and 18.
75. (Previously presented) The molecule of claim 68, wherein said molecule comprises a leader sequence.
76. (Previously presented) The molecule of claim 75, wherein said leader sequence comprises a sequence substantially identical to the sequence of SEQ ID NO: 3.
77. (Previously presented) The molecule of claim 68, wherein said molecule comprises a transcriptional regulatory sequence.
78. (Previously presented) The molecule of claim 77, wherein said transcriptional regulatory sequence comprises a sequence substantially identical to the sequence selected from the group consisting of SEQ ID NOs: 4-13 and 20-30.

79. (Currently amended) The molecule of claim [[1]] 68, wherein said molecule comprises a sequence substantially identical to a sequence selected from nucleotides 265-13,398; 13,398-21,485; 21,492 – 25,259; 25,268 – 26,092; 25,689 – 26,153; 26,117 – 26,347; 26,398 – 27,063; 27,074 – 27,265; 27,273 – 27,641; 27,638 – 27,772; 27,779 – 27,898; 27,864 – 28,118; 28,120 – 29,388; 28,130 – 28,426; 28,583 – 28,795; and 29,590 – 29,621 of SEQ ID NO: 15.
80. (Previously presented) The molecule of claim 68, wherein said molecule encodes a polyprotein.
81. (Previously presented) The molecule of claim 68, wherein said molecule encodes a polypeptide.
- 82-104. (Cancelled)
105. (Previously presented) A vector comprising the nucleic acid molecule of claim 68.
106. (Previously presented) The vector of claim 105, wherein said vector comprises a sequence substantially identical to a sequence selected from the group consisting of SEQ ID NOS: 1-13, 15-18, 20-30, 90-159, 208, and 209.
107. (Previously presented) The vector of claim 105, wherein said vector is a gene therapy vector.
108. (Previously presented) A host cell comprising the vector of claim 105.
109. (Previously presented) The host cell of claim 108, wherein said cell is selected from the group consisting of a mammalian cell, a yeast, a bacterium, and a nematode cell.
110. (Previously presented) A nucleic acid molecule having substantial nucleotide sequence identity to a sequence encoding a SARS virus polypeptide or fragment thereof, wherein said fragment comprises at least six amino acids, and wherein said nucleic acid molecule hybridizes under high stringency conditions to at least a portion of a SARS virus nucleic acid molecule.
111. (Previously presented) The nucleic acid molecule of claim 110, wherein said nucleic acid molecule has 100% sequence complementarity to said sequence encoding a SARS virus polypeptide or fragment thereof.
112. (Previously presented) A nucleic acid molecule having substantial nucleotide sequence identity to a SARS virus nucleotide sequence, wherein said nucleic acid molecule comprises

at least ten nucleotides, and wherein said nucleic acid molecule hybridizes under high stringency conditions to at least a portion of a SARS virus nucleic acid molecule.

113. (Previously presented) The nucleic acid molecule of claim 112, wherein said nucleic acid molecule has 100% sequence complementarity to said SARS virus nucleotide sequence.
114. (Previously presented) A nucleic acid molecule comprising a sequence that is antisense to a SARS virus nucleic acid molecule.
- 115-120. (Cancelled)
121. (Previously presented) A nucleic acid molecule comprising a sequence complementary to a SARS virus nucleotide sequence.
122. (Previously presented) A kit for detecting the presence of a SARS virus nucleic acid molecule or polypeptide in a sample, said kit comprising a reagent selected from the group consisting of a SARS virus nucleic acid molecule and an antibody that specifically binds a SARS virus polypeptide.
- 123-128. (Cancelled)
129. (Previously presented) A vaccine comprising a SARS virus nucleic acid molecule or polypeptide.
130. (Previously presented) The vaccine of claim 128, wherein the vaccine is a DNA vaccine.
131. (Previously presented) A microarray comprising a plurality of elements, wherein each element comprises one or more distinct nucleic acid or amino acid sequences, and wherein the sequences are selected from a SARS virus nucleic acid molecule or polypeptide, or a antibody that specifically binds a SARS virus nucleic acid molecule or polypeptide.
- 132-133. (Cancelled)